Results 121 to 130 of about 15,932 (195)

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

Dapagliflozin binds PRMT7 to inhibit p38 MAPK phosphorylation and macrophage foam cell formation in atherosclerosis. [PDF]

iScience
Fang Y, Li S, Qin C, Chou Y, Sun N, Ma Y, Zhou Y, Li H, Feng H, Yuan X, Ye H, Wu X, Kang N, Chen H, Gao L, Cao F.   +15 more
europepmc   +1 more source

Correspondence: Effects of short‐term tofogliflozin treatment on insulin secretory capacity in type 2 diabetes: Insights and future directions

Journal of Diabetes Investigation, EarlyView.
Gargi Bisht, Nitin Kumar Indora
wiley   +1 more source

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor‐Associated Ketoacidosis Case Reports

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.
ABSTRACT Introduction The use of sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i‐associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). Therefore, cessation of this drug is recommended before surgery.
L. I. P. Snel, X. Li, F. Jamaludin, S. E. Siegelaar, F. Holleman, T. M. Vriesendorp, J. H. DeVries, J. B. L. Hoekstra, B. Preckel, D. H. van Raalte, J. Hermanides, A. H. Hulst   +11 more
wiley   +1 more source

Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications. [PDF]

FASEB Bioadv
Klonari A, Athinodorou AM, Papanikolaou E, Skonta A, Bellou MG, Lakkas L, Tsamis KI, Markopoulos GS, Stamatis H, Bozidis P, Peschos D, Simos YV.   +11 more
europepmc   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study. [PDF]

BMC Cardiovasc Disord
Yang J, Li X, Tang L, Fan W, Li A, Zhou W, Pang J, Yuan Q, Zhong M, Hou J, Wang L, Liao W, Liu X, Cardiovascular B.   +13 more
europepmc   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5740-5750, July 2026.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration. [PDF]

Drug Des Devel Ther
Lee HW, Kim H, Park JS, Lee JH, Park JJ, Gwon MR, Cho JY, Seong SJ, Yoon YR.   +8 more
europepmc   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5492-5507, July 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source